SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "LAR1:gu ;lar1:(lu);pers:(Minthon Lennart 1951)"

Sökning: LAR1:gu > Lunds universitet > Minthon Lennart 1951

  • Resultat 1-10 av 24
  • [1]23Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Andersson, Malin E, 1978-, et al. (författare)
  • Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease.
  • 2007
  • Ingår i: International journal of molecular medicine. - 1107-3756. ; 20:2, s. 233-9
  • Tidskriftsartikel (refereegranskat)abstract
    • Kinesin is a microtubule-associated motor protein that transports Alzheimer-associated amyloid precursor protein (APP) in neurons. In animal models, impaired kinesin-mediated APP transport seems to enhance formation of the neurotoxic 42 amino acid fragment of beta-amyloid (A beta 42). In man, one study suggests that a polymorphism (rs8702, 56,836G > C) in the kinesin light chain 1 gene (KNS2) may affect the risk of Alzheimer's disease (AD). To further assess KNS2 as a susceptibility gene for AD we analyzed 802 patients with sporadic AD and 286 controls, 134 longitudinally followed patients with mild cognitive impairment (MCI) and 39 cognitively stable controls for the rs8702 polymorphism. The rs8702 polymorphism did not influence risk of AD (p=0.46). However, rs8702 interacted with APOE epsilon 4 carrier status in AD (p=0.006) and influenced cerebrospinal fluid levels of hyper-phosphorylated tau in MCI patients who converted to AD during follow-up (p=0.018). These findings support earlier indications that genetic variability in the KNS2 gene may play a role during early stages of AD pathogenesis.
  •  
2.
  • Blennow, Kaj, 1958-, et al. (författare)
  • Longitudinal stability of CSF biomarkers in Alzheimer's disease
  • 2007
  • Ingår i: NEUROSCIENCE LETTERS. - 0304-3940. ; 419:1, s. 18-22
  • Tidskriftsartikel (refereegranskat)abstract
    • Biomarker levels in cerebrospinal fluid (CSF) may serve as surrogate markers for treatment efficacy in clinical trials of disease-modifying drugs against Alzheimer's disease (AD). A prerequisite, however, is that the marker is sufficiently stable over time in individual patients. Here, we tested the stability of the three established CSF biomarkers for AD, total tau (T-tau), tau phosphorylated at threonine 181 (P-tau(181)) and the 42 amino acid isoform of beta-amyloid (A beta 42), over 6 months in a cohort of AD patients on stable treatment with acetylcholinesterase (AChE) inhibitors. Fifty-three patients completed the study, 29 men and 24 women, mean age (+/- S.D.) 76.1 +/- 7.9 years. Mean levels of CSF biomarkers were very stable between baseline and endpoint, with coefficients of variation (CVs) of 4.4-6.1%. Intra-individual biomarker levels at baseline and endpoint were also highly correlated with Pearson r-values above 0.95 (p < 0.0001), for all three markers. We conclude that T-tau, P-tau and A beta 42 concentrations in CSF are remarkably stable over a 6-month period in individual AD patients. This suggest that these biomarkers may have a potential to identify and monitor very minor biochemical changes induced by treatment, and thus support their possible usefulness as surrogate markers in clinical trials with drug candidates with disease-modifying potential, such as secretase inhibitors, A beta immunotherapy and tau phosphorylation inhibitors. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
  •  
3.
  • Boström, Fredrik, et al. (författare)
  • Cerebrospinal Fluid Total Tau Is Associated with Shorter Survival in Dementia with Lewy Bodies.
  • 2009
  • Ingår i: Dementia and geriatric cognitive disorders. - 1421-9824. ; 28:4, s. 314-319
  • Tidskriftsartikel (refereegranskat)abstract
    • A pathology typical of dementia with Lewy bodies (DLB) has been demonstrated to increase mortality to a greater extent than the pathology of Alzheimer's disease (AD). However, mortality in DLB has also been shown to increase with concomitant AD pathology. Furthermore, in a recent publication, we showed that there is a robust and specific increase in CSF calcium and magnesium in DLB patients compared to both AD patients and controls. Thus, in order to explore the influence of CSF AD markers and trace element concentrations on mortality in DLB, we undertook a longitudinal prospective study of 47 clinically diagnosed DLB patients and 157 AD patients as well as 49 healthy volunteers. Both AD and DLB patients showed an increased mortality compared to the healthy controls (relative risk: 10 and 8, respectively; p < 0.001). Increased levels of CSF total tau were associated with increased mortality among the DLB patients (p < 0.05), but not among the AD patients or controls. Gender, age, MMSE score, Abeta42 concentration and phosphorylated tau, and CSF trace element concentrations did not influence survival in the obtained models.
4.
  • Buchhave, Peder, et al. (författare)
  • Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease.
  • 2009
  • Ingår i: Neuroscience letters. - 0304-3940. ; 450:1, s. 56-9
  • Tidskriftsartikel (refereegranskat)abstract
    • CD40 is a member of the tumor necrosis factor receptor super-family and has been suggested to play a role in the metabolism of beta-amyloid (Abeta) in Alzheimer's disease (AD). However, the role of CD40-signalling in incipient AD has not yet been studied. We investigated the plasma levels of soluble CD40 (sCD40) and the soluble CD40 ligand (sCD40L) at baseline in 136 subjects with mild cognitive impairment (MCI) and 30 age-matched controls. Sixty of the 136 MCI cases converted to AD (MCI-AD) during a clinical follow-up period of 4-7 years. The baseline levels of sCD40, but not sCD40L, were elevated in MCI-AD cases when compared to age-matched controls (Mann-Whitney U-test, p=0.02). However, MCI patients who were cognitively stable or developed vascular dementia during follow-up did not have significantly increased levels of sCD40 or sCD40L when compared to controls. The levels of sCD40 correlated to decreased baseline performance on mini-mental state examination (MMSE) in both controls (r(s)=-0.37, p<0.05) and MCI-AD cases (r(s)=-0.29, p<0.05). Finally, the plasma levels of sCD40 correlated with the levels of soluble amyloid precursor protein-alpha (sAPP-alpha) (r(s)=0.28, p<0.01) and sAPP-beta (r(s)=0.23, p<0.05) in cerebrospinal fluid. In conclusion, CD40-signalling might play a role in the pathogenesis of early AD.
5.
  • Gerhardsson, Lars, 1952-, et al. (författare)
  • Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
  • 2009
  • Ingår i: Dementia and geriatric cognitive disorders. - 1421-9824. ; 28:1, s. 88-94
  • Tidskriftsartikel (refereegranskat)abstract
    • Background/Aims: In this study, metal concentrations were related to the levels of well-known Alzheimer markers in cerebrospinal fluid (CSF), such as amyloid-beta (A beta), total tau (T-tau) and phosphorylated-tau (P-tau). Methods: Concentrations of 19 metals (Mg, Ca, V, Mn, Fe, Co, Ni, Cu, Zn, Se, Rb, Sr, Mo, Cd, Sn, Sb, Cs, Hg and Pb by inductively coupled plasma-mass spectrometry) and the levels of A beta, T-tau and P-tau in CSF were determined (xMAP technology) in 264 patients with Alzheimer's disease ( AD), and in 54 healthy referents. Results: The AD subjects showed positive correlations between CSF-T-tau and CSF-P-tau versus CSF-Mn (r(s) = 0.22, p = 0.004; r(s) = 0.18, p = 0.021). CSF-T-tau, however, showed a negative correlation with CSF-Cs (r(s) = -0.17; p = 0.027). In subjects with severe AD, CSF-A beta showed a strong positive correlation with CSF-Cs (r(s) = 0.49; p = 0.026), while CSF-T-tau showed a strong negative correlation with CSF-Cs (r(s) = -0.49; p = 0.026). Also, CSF P-tau was negatively associated with CSF-Cs (r(s) = -0.41; p = 0.06). Conclusion: The different relationships between the CSF-levels of A beta and tau-markers versus the levels of CSF-Mn and CSF-Cs may be due to different binding affinity between these metals and metal binding proteins in the CSF and the surrounding brain. Copyright (c) 2009 S. Karger AG, Basel
  •  
6.
7.
  • Hansson, Oskar, et al. (författare)
  • Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
  • 2009
  • Ingår i: Neurobiology of aging. - 1558-1497. ; 30:2, s. 165-73
  • Tidskriftsartikel (refereegranskat)abstract
    • This study aimed to identify preclinical Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) using measurements of both regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) biomarkers. Baseline rCBF assessments (133Xe method) were performed in 70 patients with MCI who were cognitively stable for 4–6 years, 69 patients with MCI who subsequently developed AD, and 33 healthy individuals. CSF was collected at baseline and analyzed for β-amyloid1–42, total tau and phophorylated tau. In contrast to patients with stable MCI, those who subsequently developed AD had decreased rCBF in the temporo-parietal cortex already at baseline. The relative risk of future progression to AD was particularly increased in MCI patients with decreased rCBF in parietal cortex (hazard ratio 3.1, P < 0.0001). Subjects with pathological levels of both CSF tau and β-amyloid1–42 were also at high risk of developing AD (hazard ratio 13.4, P < 0.0001). The MCI patients with a combination of decreased parietal rCBF and pathological CSF biomarkers at baseline had a substantially increased risk of future development of AD, with a hazard ratio of 24.3 (P < 0.0001), when compared to those with normal CSF biomarkers. Moreover, decreased parietal rCBF (but not CSF biomarkers) was associated with a more rapid progression to AD. In conclusion, the combination of rCBF and CSF biomarkers improves the risk assessment of progression to AD in patients with MCI.
8.
  • Johansson, Annica, 2000-, et al. (författare)
  • Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's disease
  • 2005
  • Ingår i: Dementia and Geriatric Cognitive Disorders. - 1420-8008. ; 20:6, s. 367-374
  • Tidskriftsartikel (refereegranskat)abstract
    • We have recently reported that a polymorphism in the cell division cycle (CDC2) gene, designated Ex6 + 7I/D, is associated with Alzheimer's disease (AD). The CDC2 gene is located on chromosome 10q21.1 close to the marker D10S1225 linked to AD. Active cdc2 accumulates in neurons containing neurofibrillary tangles (NFT), a process that can precede the formation of NFT. Therefore, CDC2 is a promising candidate susceptibility gene for AD. We investigated the possible effects of the CDC2 polymorphism on cerebrospinal fluid (CSF) biomarkers in AD patients. CDC2 genotypes were evaluated in relation to CSF protein levels of total tau, phospho-tau and beta-amyloid (1-42) in AD patients and control individuals, and in relation to the amount of senile plaques and NFT in the frontal cortex and in the hippocampus in patients with autopsy-proven AD and controls. The CDC2 Ex6 + 7I allele was associated with a gene dose-dependent increase of CSF total tau levels (F-2,F- 626 = 7.0, p = 0.001) and the homozygous CDC2Ex6 +7II genotype was significantly more frequent among AD patients compared to controls (p = 0.006, OR = 1.57, 95% CI 1.13-2.17). Our results provide further evidence for an involvement of cdc2 in the pathogenesis of AD.
  •  
9.
  • Kruczyk, M., et al. (författare)
  • Monte Carlo feature selection and rule-based models to predict Alzheimer's disease in mild cognitive impairment.
  • 2012
  • Ingår i: Journal of neural transmission (Vienna, Austria : 1996). - 1435-1463. ; 119:7, s. 821
  • Tidskriftsartikel (refereegranskat)abstract
    • The objective of the present study was to evaluate a Monte Carlo feature selection (MCFS) and rough set Rosetta pipeline for generating rule-based models as a tool for comprehensive risk estimates for future Alzheimer's disease (AD) in individual patients with mild cognitive impairment (MCI). Risk estimates were generated on the basis of age, gender, Mini-Mental State Examination scores, apolipoprotein E (APOE) genotype and the cerebrospinal fluid (CSF) biomarkers total tau (T-tau), phospho-tau(181) (P-tau) and the 42 amino acid form of amyloid beta (A beta 42) in two sets of longitudinally followed MCI patients (n = 217 in total). The predictive model was created in Rosetta, evaluated with the standard tenfold cross-validation approach and tested on an external set. Features were ranked and selected by the MCFS algorithm. Using the combined pipeline of MCFS and Rosetta, it was possible to predict AD among patients with MCI with an area under the receiver operating characteristics curve of 0.92. Risk estimates were produced for the individual patients and showed good correlation with actual diagnosis in cross validation, and on an external dataset from a new study. Analysis of the importance of attributes showed that the biochemical CSF markers contributed the most to the predictions, and that added value was gained by combining several biochemical markers. Despite a correlation with the biochemical markers, the genetic marker APOE epsilon 4 did not contribute to the predictive power of the model.
  •  
10.
  • Landgren, Sara, 1980-, et al. (författare)
  • No Association of VEGF Polymorphims with Alzheimer's Disease.
  • 2010
  • Ingår i: Neuromolecular medicine. - 1559-1174. ; 12:3, s. 224-8
  • Tidskriftsartikel (refereegranskat)abstract
    • The vascular hypothesis of Alzheimer's disease (AD) has brought the vascular endothelial growth factor (VEGF) into focus. The genomic region including the VEGF gene has been linked to AD and single nucleotide polymorphisms (SNPs) of the VEGF have in previous studies been associated with AD risk. To further evaluate these findings, we genotyped two SNPs in the VEGF gene (rs699947 -2578) and rs1570360 -1154) by TaqMan Allelic Discrimination in a study sample including AD patients (n = 801) and controls (n = 286). In a subgroup of the population these SNPs were analyzed in relation to APOE epsilon 4 genotype, to cerebrospinal fluid biomarkers (T-tau, P-tau, and beta(42)-Amyloid) as well as to neuropathological markers for AD (neurofibrillary tangles and senile plaques). No significant associations with risk for AD or any of the studied biomarkers could be found in this study, thus not supporting VEGF as being a major risk gene for AD.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 24
  • [1]23Nästa
Åtkomst
fritt online (7)
Typ av publikation
tidskriftsartikel (24)
Typ av innehåll
refereegranskat (23)
övrigt vetenskapligt (1)
Författare/redaktör
Blennow, Kaj, 1958-, (23)
Zetterberg, Henrik, ... (20)
Hansson, Oskar (10)
Andreasen, Niels (7)
Wallin, Anders, 1950 ... (7)
visa fler...
Londos, Elisabet (6)
Palmer, Mona Seibt (4)
Skoog, Ingmar, 1954- ... (4)
Bogdanovic, Nenad (4)
Zetterberg, Madelein ... (4)
Buchhave, Peder (4)
Landgren, Sara, 1980 ... (4)
Gustafson, Deborah, ... (3)
Andersson, Malin E, ... (3)
Nilsson, Staffan, 19 ... (2)
von Otter, Malin, 19 ... (2)
Lundh, Thomas (2)
Andreasson, Ulf, 196 ... (2)
Sjölander, Annica, 1 ... (2)
Sjolander, Annica (2)
Tasa, Gunnar (2)
Karlsson, Mats, (2)
Gerhardsson, Lars, 1 ... (2)
Rolstad, Sindre, 197 ... (2)
Hampel, Harald (2)
Jonsson, Michael, 19 ... (2)
Warkentin, Siegbert, (2)
Podust, Vladimir N (2)
Rosén, Erik, (2)
McGuire, James (2)
Gustafson, L (1)
Marcusson, Jan, (1)
Winblad, Bengt (1)
Janciauskiene, Sabin ... (1)
Ejnell, Hasse, 1948- ... (1)
Rymo, Lars, 1940-, (1)
Aarsland, Dag (1)
Mulugeta, Ezra (1)
Thelle, Dag, 1942- (1)
Nilsson, Michael, 19 ... (1)
Eriksdotter-Jönhagen ... (1)
Nissbrandt, Hans, 19 ... (1)
Jern, Christina, 196 ... (1)
Jood, Katarina, 1966 ... (1)
Mattsson, Niklas, 19 ... (1)
Hansson, O. (1)
Annas, Peter, (1)
Lannfelt, Lars, (1)
Håkansson, Anna, 197 ... (1)
visa färre...
Lärosäte
Göteborgs universitet (24)
Uppsala universitet (2)
Chalmers tekniska högskola (2)
Linköpings universitet (1)
Språk
Engelska (24)
Ämne (HSV)
Medicin och hälsovetenskap (24)
Naturvetenskap (2)
Samhällsvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy